WO2007053194A3 - Modulation of cell barrier dysfunction - Google Patents

Modulation of cell barrier dysfunction Download PDF

Info

Publication number
WO2007053194A3
WO2007053194A3 PCT/US2006/021604 US2006021604W WO2007053194A3 WO 2007053194 A3 WO2007053194 A3 WO 2007053194A3 US 2006021604 W US2006021604 W US 2006021604W WO 2007053194 A3 WO2007053194 A3 WO 2007053194A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
cell barrier
pseudomonas
mediated
Prior art date
Application number
PCT/US2006/021604
Other languages
French (fr)
Other versions
WO2007053194A2 (en
Inventor
John C Alverdy
Jonathan Moss
Mark W Lingen
Patrick A Singleton
Joe G N Garcia
Original Assignee
Univ Chicago
John C Alverdy
Jonathan Moss
Mark W Lingen
Patrick A Singleton
Joe G N Garcia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/007892 external-priority patent/WO2006096626A2/en
Priority to US11/914,984 priority Critical patent/US20080194611A1/en
Application filed by Univ Chicago, John C Alverdy, Jonathan Moss, Mark W Lingen, Patrick A Singleton, Joe G N Garcia filed Critical Univ Chicago
Priority to EP06844131A priority patent/EP1901742A2/en
Priority to AU2006309292A priority patent/AU2006309292A1/en
Priority to JP2008514938A priority patent/JP2008542395A/en
Priority to CA002609985A priority patent/CA2609985A1/en
Publication of WO2007053194A2 publication Critical patent/WO2007053194A2/en
Publication of WO2007053194A3 publication Critical patent/WO2007053194A3/en
Priority to US13/483,932 priority patent/US20120316190A1/en
Priority to US14/061,331 priority patent/US20140142133A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides prophylactic and therapeutic methods for administering a μ-opioid receptor antagonist to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders. The diseases or disorders may amenable to the methods include inflammation, such as acute lung injury, atherosclerosis, gut-derived sepsis, a burn injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection, pouchitis, pig belly (pig-bel), Pseudomonas-mediated ophthalmologic infection, Pseudomonas-mediated otologic infection and Pseudomonas-mediated cutaneous infection. More generally, epithelial cell barrier disorders are contemplated as amenable to the prophylactic and therapeutic methods.. The diseases and disorders may be induced by microbial pathogens, including bacterial pathogens such as Pseudomonαs aeruginosa. The invention further provides prophylactic and therapeutic methods for inhibiting the expression of bacterial PA-I lectin/adhesin and for inhibiting bacterial MvfR activity levels. Also provided is a method of using a μ-opioid receptor antagonist in the manufacture of a medicament for use in the methods described herein.
PCT/US2006/021604 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction WO2007053194A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US11/914,984 US20080194611A1 (en) 2005-06-03 2006-05-06 Modulation of Cell Barrier Dysfunction
EP06844131A EP1901742A2 (en) 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction
AU2006309292A AU2006309292A1 (en) 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction
JP2008514938A JP2008542395A (en) 2005-06-03 2006-06-05 Regulation of cell barrier dysfunction
CA002609985A CA2609985A1 (en) 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction
US13/483,932 US20120316190A1 (en) 2005-06-03 2012-05-30 Modulation of Cell Barrier Dysfunction
US14/061,331 US20140142133A1 (en) 2005-06-03 2013-10-23 Modulation of cell barrier dysfunction

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US68756805P 2005-06-03 2005-06-03
US60/687,568 2005-06-03
US73100905P 2005-10-28 2005-10-28
US60/731,009 2005-10-28
US76085106P 2006-01-20 2006-01-20
US60/760,851 2006-01-20
USPCT/US2006/07892 2006-03-07
PCT/US2006/007892 WO2006096626A2 (en) 2005-03-07 2006-03-07 Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/007892 Continuation-In-Part WO2006096626A2 (en) 2005-03-07 2006-03-07 Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/914,984 A-371-Of-International US20080194611A1 (en) 2005-06-03 2006-05-06 Modulation of Cell Barrier Dysfunction
US13/483,932 Continuation US20120316190A1 (en) 2005-06-03 2012-05-30 Modulation of Cell Barrier Dysfunction

Publications (2)

Publication Number Publication Date
WO2007053194A2 WO2007053194A2 (en) 2007-05-10
WO2007053194A3 true WO2007053194A3 (en) 2007-08-09

Family

ID=38006351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/021604 WO2007053194A2 (en) 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction

Country Status (3)

Country Link
EP (1) EP1901742A2 (en)
CA (1) CA2609985A1 (en)
WO (1) WO2007053194A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526723B2 (en) 2008-03-21 2016-12-27 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091623A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals. Inc. Pharmaceutical formulations containing methylnaltrexone
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (en) 2005-03-07 2009-02-17 Univ Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration.
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
EP2012790A4 (en) * 2006-04-19 2009-07-01 Smith Jill P Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
AU2008233129B2 (en) 2007-03-29 2014-03-20 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
MX2009010550A (en) 2007-03-29 2009-12-14 Progenics Pharm Inc Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof.
SI2565195T1 (en) 2007-03-29 2015-09-30 Wyeth Llc Peripheral opioid receptor and antagonists and uses thereof
TWI453020B (en) * 2007-10-05 2014-09-21 Toray Industries Use for the production of the therapeutic agent for preventing skin drying, improving skin roughening and improving the skin darkening involved in hyperkeratosis of morphinan derivatives or the pharmaceutically acceptable acid addition salt thereof
KR101581480B1 (en) 2008-02-06 2015-12-30 프로제닉스 파머슈티컬스, 인코포레이티드 Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
ES2620373T3 (en) 2008-07-01 2017-06-28 University Of Chicago Particles containing a peripheral opioid receptor antagonist
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US9504736B2 (en) 2010-09-23 2016-11-29 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
ES2906262T3 (en) 2014-03-25 2022-04-13 Leading Biosciences Inc Compositions for the treatment of autodigestion
CN117940554A (en) * 2022-06-30 2024-04-26 上海羽冠生物技术有限公司 Live bacterial strains of the genus Pseudomonas

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
US20020173466A1 (en) * 1999-03-03 2002-11-21 Crain Stanley M. Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
WO2006132963A2 (en) * 2005-06-03 2006-12-14 The University Of Chicago Modulation of microbial pathogen-host cell interactions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20020173466A1 (en) * 1999-03-03 2002-11-21 Crain Stanley M. Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
WO2006132963A2 (en) * 2005-06-03 2006-12-14 The University Of Chicago Modulation of microbial pathogen-host cell interactions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZAGON I S ET AL: "OPIOID ANTAGONISTS INHIBIT THE GROWTH OF METASTATIC MURINE NEURO BLASTOMA", CANCER LETTERS, vol. 21, no. 1, 1983, pages 89 - 94, XP009083862, ISSN: 0304-3835 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526723B2 (en) 2008-03-21 2016-12-27 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors

Also Published As

Publication number Publication date
CA2609985A1 (en) 2007-05-10
WO2007053194A2 (en) 2007-05-10
EP1901742A2 (en) 2008-03-26

Similar Documents

Publication Publication Date Title
WO2007053194A3 (en) Modulation of cell barrier dysfunction
WO2004085628A8 (en) Lactic acid utilising bacteria and their therapeutic use
MY161095A (en) Indole compound and pharmaceutical use thereof
WO2011160062A3 (en) Compositions and methods for treating inflammatory conditions
NZ593111A (en) Antibacterial compounds
WO2007131072A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2011043538A3 (en) Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
WO2009143150A3 (en) Intestinal alkaline phosphatase modulators and uses thereof
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
Das et al. Antagonistic activity of cellular components of Pseudomonas species against Aeromonas hydrophila
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
EA201171270A1 (en) APPLICATION OF NIFURATEL IN THE TREATMENT OF INFECTIONS CAUSED BY ATOPOBIUM
NZ706573A (en) Ciclesonide for the treatment of airway disease in horses
WO2008071961A8 (en) 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents
WO2007101264A3 (en) Method for treating endothelial and epithelial cell disorders by administering high molecular weight peg-like compounds
WO2008036761A8 (en) Anti-microbial defensin-related peptides and methods of use
WO2005118613A3 (en) Antibacterial amide macrocycles
MX2013002579A (en) Quinoxaline compound.
WO2009114878A3 (en) Methods and compositions for genetic and retinal disease
NZ610853A (en) Phenylketone carboxylate compounds and pharmaceutical uses thereof
WO2007014167A3 (en) Compositions for and methods of treating epithelial diseases with growth factors
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
WO2009068682A3 (en) Phenyl-oxetanyl-derivatives
IL218467A0 (en) Picrorhiza kurroa extract for prevention elimination and treatment of infection diseases
WO2011163539A3 (en) nAChRα7 AGONISTS AND nAChRα7 ANTAGONISTS FOR TREATING ULCERATIVE COLITIS (UC) AND CROHN'S DISEASE (CD)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006309292

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2609985

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008514938

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006844131

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11914984

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06844131

Country of ref document: EP

Kind code of ref document: A2